BRCA Mutations, Homologous DNA Repair Deficiency, Tumor Mutational Burden, and Response to Immune Checkpoint Inhibition in Recurrent Ovarian Cancer

PURPOSE: Homologous DNA repair–deficient (HRD) ovarian cancers (OCs), including those with BRCA1/2 mutations, have higher levels of genetic instability, potentially resulting in higher immunogenicity, and have been suggested to respond better to immune checkpoint inhibitors (ICIs) than homologous DN...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCO Precis Oncol
Auteurs principaux: Liu, Ying L., Selenica, Pier, Zhou, Qin, Iasonos, Alexia, Callahan, Margaret, Feit, Noah Z., Boland, Julia, Vazquez-Garcia, Ignacio, Mandelker, Diana, Zehir, Ahmet, Burger, Robert A., Powell, Daniel J., Friedman, Claire, Cadoo, Karen, Grisham, Rachel, Konner, Jason A., O’Cearbhaill, Roisin E., Aghajanian, Carol, Reis-Filho, Jorge S., Weigelt, Britta, Zamarin, Dmitriy
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446408/
https://ncbi.nlm.nih.gov/pubmed/32923884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00069
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires